Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD) | MicrobiomeTrials← Back to trialsNCT07245394
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
RecruitingOBSERVATIONAL
Trial Details
Start: 2026-01-29Est. Completion: 2027-11-01
Enrollment target: 200 participants Locations- University of Calgary, Calgary, Alberta, Canada
- MA MacMillan, Fredericton, New Brunswick, Canada
- Hamilton Health Sciences Corporation, Hamilton, Ontaio, Canada
- Barrie GI Associates, Barrie, Ontario, Canada
- Brampton Gastroenterology Research Group Inc, Brampton, Ontario, Canada
- GNRR Digestive Clinics and Research Center Inc., Brampton, Ontario, Canada
- LDDI Clinical Trials Inc. dba London Digestive Disease Institute, London, Ontario, Canada
- West Gta Research Inc., Mississauga, Ontario, Canada
- Abp Research Services Corporation, Oakville, Ontario, Canada
- Taunton Surgical Center, Oshawa, Ontario, Canada
- Toronto Immune and Digestive Health Institute, Toronto, Ontario, Canada
- CIUSSS l'Est-de-l'Île-de-Montréal, Montreal, Quebec, Canada
- The Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
- Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada
Other microbiome trials you might be interested in
Inflammatory Bowel DiseaseCrohn's DiseaseUlcerative Colitis
Background:
Inflammatory bowel disease (IBD) is a term used to describe disorders that cause long-term inflammation in …
Bethesda, United StatesEst. completion Jun 1, 2036
Gastrointestinal Disease Symptoms
The aim of this study is to determine how regular consumption of Synbiotic+, a dietary supplement that contains prebioti…
Fort Collins, United StatesCompleted Aug 1, 2026
Recruiting
Inflammatory Bowel Disease (IBD)
This observational study will use intestinal ultrasound images to help develop computer programs that may make it easier…
Vancouver, CanadaEst. completion Feb 1, 2027